share_log

Cybin | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SEC announcement ·  Mar 19 02:50
Summary by Futu AI
Cybin Inc., a clinical-stage biopharmaceutical company, has announced its participation in the Public Ventures Discovery Day event scheduled for March 19, 2024, in Dallas, Texas. The company's CEO, Doug Drysdale, will engage in a fireside chat and will be available for breakout sessions with attendees. The event, hosted by Public Ventures, LLC, a subsidiary of MDB Capital Holdings, LLC (NASDAQ: MDBH), is an exclusive gathering for investors to interact with leaders of venture-stage, deep-tech companies. Cybin, known for developing psychedelic-based treatments for mental health conditions, is working on compounds such as CYB003 for major depressive disorder and CYB004 for generalized anxiety disorder. A video replay of the chat will be accessible on Cybin's investor relations website post-event. Attendance is limited, with preference given to MDBH shareholders. Cybin, established in 2019, operates across North America and Europe and is committed to revolutionizing mental healthcare through its innovative therapeutic approaches.
Cybin Inc., a clinical-stage biopharmaceutical company, has announced its participation in the Public Ventures Discovery Day event scheduled for March 19, 2024, in Dallas, Texas. The company's CEO, Doug Drysdale, will engage in a fireside chat and will be available for breakout sessions with attendees. The event, hosted by Public Ventures, LLC, a subsidiary of MDB Capital Holdings, LLC (NASDAQ: MDBH), is an exclusive gathering for investors to interact with leaders of venture-stage, deep-tech companies. Cybin, known for developing psychedelic-based treatments for mental health conditions, is working on compounds such as CYB003 for major depressive disorder and CYB004 for generalized anxiety disorder. A video replay of the chat will be accessible on Cybin's investor relations website post-event. Attendance is limited, with preference given to MDBH shareholders. Cybin, established in 2019, operates across North America and Europe and is committed to revolutionizing mental healthcare through its innovative therapeutic approaches.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.